OT-C001 / Onward Therap - LARVOL DELTA

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab (Canada Newswire) - "Onward Therapeutics SA...announced that its subsidiary, Emercell SAS, has received Investigational Medicinal Product Dossier (IMPD) approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of OT-C001, an allogeneic natural killer (NK) cell therapy, in combination with an anti-CD20 monoclonal antibody, Rituximab. The upcoming phase 1 study (C00101 study) will enroll patients with diffuse large B-cell lymphoma (DLBCL), who have relapsed after, or are refractory to CAR-T cell therapy, or ineligible for CAR-T cell infusion."

New P1 trial • Diffuse Large B Cell Lymphoma

Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001 (Businesswire) - "Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercell’s lead product....NK-001 is an optimized cell therapy product composed of highly activated and alloreactive allogeneic NK cells....Emercell has selected Cell-Easy as a long-term CDMO partner for the scale-up and manufacturing operations of its allogeneic NK cell-based product, with the objective to enter clinical phase in 2023. Emercell has signed a strategic agreement with Cell-Easy specialized in the development and production of ATMP."

Licensing / partnership • Oncology • Solid Tumor

Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapy (PRNewswire) - "Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced today the recent exercise of Onward Therapeutics' second of three instalments of equity investment in Emercell. With this investment, Onward Therapeutics has become Emercell's majority shareholder....'This second equity investment in Emercell confirms that the NK-001 project has been advancing well since our first equity investment in February 2021, and we will be able to scale up and industrialize the production of activated NK cells rapidly, to offer new treatments for cancer patients.'"

Financing • Oncology • Solid Tumor